Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 17, 2026Journal of Alzheimer s Disease

Ginkgo biloba and longitudinal changes in amyloid PET and plasma amyloid-β oligomerization in amyloid-positive mild cognitive impairment: A retrospective analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYoungSoon YangYKYong Tae Kwak

Discussion

Loading...

Member takes

Overview

Retrospective analysis compares clinical outcomes and amyloid biomarkers in MCI patients using Ginkgo biloba and Non-Ginkgo enhancers, suggesting potential benefits of Ginkgo.

Key Points

  • To evaluate the impact of Ginkgo biloba on clinical outcomes and amyloid-related biomarkers in amyloid PET-positive mild cognitive impairment over 18 months.
  • Retrospective cohort study involving 35 amyloid PET-positive MCI patients.
  • Comparison of baseline and 18-month clinical evaluations and plasma Aβ oligomerization.
  • Assessment of amyloid PET burden using paired baseline and 18-month 18F-FC119S scans.
  • Patients received either Ginkgo biloba extract (240 mg/day) or Non-Ginkgo cognitive enhancers.
  • Ginkgo-treated patients maintained clinical stability while 57.1% of Non-Ginkgo patients showed cognitive decline.
  • No Ginkgo patients converted to AD dementia, whereas 28.6% of Non-Ginkgo patients did.
  • Plasma Aβ oligomerization decreased in Ginkgo group but increased in Non-Ginkgo group.
  • Amyloid PET burden remained stable in Ginkgo group while increasing in Non-Ginkgo group.

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/69e1ce605cdc762e9d8576b6https://doi.org/10.1177/13872877261441816
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of Ginkgo biloba extract in amyloid PET-positive patients with mild cognitive impairment2025 · 8 citations
  2. 2Associations of Ginkgo biloba extract exposure with 12-month cognitive trajectories in amyloid PET–positive mild cognitive impairment and Alzheimer’s disease: a pooled retrospective cohort study2026
  3. 3Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?2026
  4. 4Efficacy of Standardized Ginkgo biloba Extract in Cognitive Enhancement for Alzheimer’s patients2025 · 1 citations
  5. 5Combined treatment with <i>Ginkgo biloba</i> extract EGb 761 plus acetylcholinesterase inhibitors improved cognitive function and neuropsychiatric symptoms in patients with mild cognitive impairment2022 · 10 citations